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Dysferlin and Caveolin-3 are plasma membrane proteins
associated with muscular dystrophy. Patients with mutations in
the CAV3 gene show dysferlin mislocalization in muscle cells.
By utilizing caveolin-null cells, expression of caveolin
mutants, and different mutants of dysferlin, we have dis-
sected the site of action of caveolin with respect to dysferlin
trafficking pathways. We now show that Caveolin-1 or -3 can
facilitate exit of a dysferlin mutant that accumulates in the
Golgi complex of Cav1/ cells. In contrast, wild type dysfer-
lin reaches the plasma membrane but is rapidly endocytosed
in Cav1/ cells. We demonstrate that the primary effect of
caveolin is to cause surface retention of dysferlin. Caveolin-1
or Caveolin-3, but not specific caveolin mutants, inhibit
endocytosis of dysferlin through a clathrin-independent
pathway colocalizing with internalized glycosylphosphatidy-
linositol-anchored proteins. Our results provide new insights
into the role of this endocytic pathway in surface remodeling of
specific surface components. In addition, they highlight a novel
mechanism of action of caveolins relevant to the pathogenic
mechanisms underlying caveolin-associated disease.
Dysferlin and Caveolin-3 (muscle-specific caveolin, Cav3)
are sarcolemmal proteins whose role inmuscle has gained clin-
ical attention because mutations in their genes are associated
with a number of muscle pathologies. Patients with mutations
in the dysferlin (DYSF) gene develop disorders such as limb
girdle muscular dystrophy type 2B, miyoshi myopathy, and dis-
tal myopathy (1–5). Whereas disruption in the Caveolin-3
(CAV3) gene has been linked to limb girdlemuscular dystrophy
1C, Rippling muscle diseases, hyperCKemia, and distal myopa-
thy among other myopathies (6–15). Dysferlin and Cav3 have
been co-purified frommuscle cells (16, 17) and shown to local-
ize to adjacent membrane domains at the surface in mature
muscle fibers (18). Moreover, dysferlin is depleted from the
plasma membrane (PM)2 when Cav3 is mutated (8, 9, 14, 17,
19). We have recently demonstrated a role for caveolin in dys-
ferlin localization at the PM (18). However, the interplay of
dysferlin and caveolinmembrane trafficking dynamics remains
to be examined.
Dysferlin belongs to the ferlin family of proteins comprising
otoferlin, myoferlin, and fer1L3 (20–22). The DYSF gene
encodes a 230-kDa skeletal muscle membrane protein (2, 5, 23)
with homology to the Caenorhabditis elegans sperm-vesicle
fusion factor, fer-1 (2). Because of this dysferlin has been sug-
gested to play a role in vesicle fusion in skeletal muscle (2, 24).
Moreover, in the absence of dysferlin muscle cells show defec-
tive resealing of membrane disruptions (25). Dysferlin has a
single transmembrane domain at the C terminus and a long
N-terminal cytoplasmic region containing six C2 domains. C2
domains are a common feature of the synaptotagmin family of
proteins implicated in vesicular traffic and membrane fusion
events through calcium-dependent interactions with phospho-
lipids and proteins (26–29). Interestingly, dysferlin and synap-
totagmins share structural similarities (20, 24) further implicat-
ing dysferlin in membrane trafficking processes.
In mammalian cells, the CAV gene family consists of three
isoforms: Caveolin-1, -2, and -3 (30–35), which are crucial
structural components of caveolar membranes (65 nm,
uncoated flask-shaped PMpits). Caveolins are 21–24-kDa inte-
gral membrane proteins, Caveolin-1 (Cav1) and -2 (Cav2) are
mainly co-expressed in non-muscle cells, whereas Cav3 is
largely expressed in skeletal and cardiac muscle but is also
found in some smoothmuscle (36, 37). Caveolins are cholester-
ol- and fatty acid-binding proteins, and are thought to play a
role in vesicular traffic and signal transduction events (38–42).
The protein structure of caveolins is characterized by a hairpin
loop topology with a hydrophobic region immersed in the lipid
bilayer (the intramembrane domain), and both N and C termi-
nus regions facing the cytoplasm (43–45). Additionally, the
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domain (CSD), has been shown to bind in vitro to a consensus
sequence (XXXXXXX,  aromatic residues, X any amino
acid) (46) present in various proteins. Dysferlin has several
putative CSD binding motifs (17).
We have recently described the subcellular distribution of
dysferlin with respect to Cav3 and showed that dysferlin asso-
ciation with the PM is impaired in the absence of caveolin, or in
the presence of dystrophy-associated mutant forms of Cav3
(18). Although Cav3 and dysferlin copurify (16, 17), the precise
interacting domains and roles in their trafficking dynamics are
poorly understood.We show here that in the absence of caveo-
lin, dysferlin reaches the PMbut is rapidly endocytosed through
a caveolin-, clathrin-, and dynamin-independent pathway.
Wild type caveolin, but notmutant forms of caveolin associated
with muscle disease, specifically inhibit dysferlin endocytosis
causing its retention at the cell surface.
EXPERIMENTAL PROCEDURES
DNA Constructs, Reagents, and Antibodies—Cell culture
reagents were obtained from Invitrogen. The antibodies used
were: mouse anti-LBPA, mouse anti-LAMP-1 (Southern Bio-
tech), mouse anti-GM130 (BD Biosciences), rabbit antibody
made against the conserved region of Cav3 (47), rabbit anti-HA
(Dr. T. Nilsson, Gothenburg University, Gothenburg, Sweden),
rabbit anti-GFP (48), mouse anti-myc 9B11 (Cell Signaling
Technology), and anti-protein-disulfide isomerase. Secondary
antibodies conjugated to Alexa Fluor 488, 350, 546, 647, and
CTB conjugated to Alexa Fluor 555 and Tf-Alexa Fluor 647
(Molecular Probes), CY3-conjugated anti-mouse antibody
(Jackson Immunoresearch), and HRP-conjugated secondary
antibodies (Zymed Laboratories) were used. SuperSignal sub-
strate was obtained from Pierce Chemical Company. All other
chemicals and reagents were obtained from Sigma.
GFP-dysferlin cDNA was used as a template to generate dif-
ferent truncation mutants by restriction digestion at unique
enzymatic sites (49) (see Fig. 1), GFP-C2 (GFP-TM), GFP-1
(GFP3GFP-2), GFP-2 (GFP-Tth), GFP-3 (GFP-Xho), and
GFP--TM. Expression of the complete fusion proteins was
confirmed in multiple cell lines. Cav3G55S-HA, Cav3C71W-
HA, and Flotillin-HA were made as described (50, 51). The
glycosylphosphatidylinositol (GPI)-GFP, Cav181–100-HA,
and transferrin receptor constructs were gifts from C. Zurzolo
(Institut Pasteur, France), D. Brown (State University of New
York), S. L. Schmid (Scripps Research Institute), and V. Gerke
(Center for Molecular Biology of Inflammation, ZMBE),
respectively. Dynamin inhibitor, dynasore, was a kind gift from
T. Kirchhausen (Harvard Medical School).
Cell Culture and Transfection—We utilized immortalized
mouse embryonic fibroblasts (MEF) cell lines derived from
Cav1WT or knock-out mice as in previous studies (18, 52, 53).
Cells were grown on glass coverslips and cDNAs were tran-
siently expressed utilizing Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s directions.
Immunofluorescence and Microscopy—Immunolabeling of
MEFs were carried out as described previously (18). Confocal
images were acquired with an inverted Zeiss LSM 510 META
microscope system (Axiovert 200M, Carl Zeiss MicroImaging)
under a Plan apochromatic 63 1.4 NA oil immersion objec-
tive. Images were processed and merged using Adobe Photo-
shop 9.0 software. Identical imaging and processing parameters
were used for all figures.
Surface Labeling and Single Cell Fluorescence Quantification—
Surface labeling andquantification of the fluorescence intensity
of dysferlin pool at the PM was performed as described previ-
ously (18). The average pixel intensity for PM and IC/Golgi
pools were measured using Adobe Photoshop 9.0 software.
Experiments were repeated three times.
Quantifications shown in Figs. 1D, 2C, 3B, and 7B are repre-
sentative of 3 individual experiments and were performed once
on 250–350 cells and twice on a total of 30 cells for each con-
struct. Subcellular phenotypes were determined based on cola-
beling with relevant IC markers. Results are presented as per-
centage of cells showing a common phenotype.
Myc, Tfn, CTB, and GPI Uptake Assays—Uptake assays were
performed as described previously (54). In brief, 20 mg/ml
monoclonal anti-myc antibody, 1 mg/ml CTxB-Alexa Fluor
555, or 5 mg/ml Tfn Alexa Fluor 647 was bound to cells on ice
for 30 min in CO2-independent medium. Cells were washed
with ice-cold CO2-independent medium to remove unbound
reagent prior to uptake in growth media (10% fetal bovine
serum, 2 mM L-glutamine/Dulbecco’s modified Eagle’s
medium) at 37 °C, for the times indicated. Cells were placed on
ice-cold CO2-independentmedium andwashed 2 times for 30 s
in 0.5 M glycine (pH 2.2). The cells were fixed in 2% paraform-
aldehyde and processed for immunofluorescence. For inhibi-
tion of dynamin-dependent uptake, cells were preincubated in
either 80 mM dynasore/growth media or 0.4% Me2SO/growth
media for 30min at 37 °C, followed by Tfn and anti-myc uptake
in the presence or absence of dynasore.
Ultrastructural Analysis of Dysferlin Endocytosis inWTCav1
and Cav1/MEFs—WT Cav1 or Cav1/MEFs were trans-
fected with GFPDysf. After overnight incubation, to allow
expression of the constructs, the cells were incubated with
mouse anti-myc antibodies at 4 °C for 20 min, washed, and fur-
ther incubated with anti-mouse HRP at 4 °C for 20 min. The
cells were warmed to 37 °C for 2 min to allow uptake and then
incubated in DAB, with or without ascorbic acid (AA), fixed,
and processed for resin embedding, exactly as described previ-
ously (54). Due to the low transfection efficiency, GFP-express-
ing cells were identified by light microscopy before processing.
They were marked to allow subsequent location for sectioning.
Quantitation of PM coverage of the HRP reaction product was
by intersection counting. The number of intersections of a
square lattice gridwith unlabeled andDAB-covered areas of the
PM in random areas of transfectedWTCav1 orCav1/MEFs
was measured on digital images to gain an estimate of PM cov-
erage by the HRP reaction.
RESULTS
Subcellular Distribution of Dysferlin Truncation Mutants in
WT Cav1 and Cav1/MEF Cells—To better understand the
functional link between dysferlin and Cav3 we examined the
subcellular distribution of truncation mutants of dysferlin and
analyzed their trafficking dependence on caveolin. We used
WTCav1 andCav1/MEFs as amodel system.Cav1/ cells
have no detectable caveolae as they lack Cav1 (as well as the
Caveolin Regulation of Dysferlin
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muscle-specific isoformCav3). This
represents a powerful model system
to analyze dysferlin trafficking with
respect to caveolin as caveolin re-
expression rescues the dysferlin
trafficking defects (18).
Truncated versions of dysferlin
with an N-terminal GFP tag were
generated (see summary in Fig. 1).
Expression of these mutants in baby
hamster kidney cells showed single
bands of the predicted molecular
weight for each of the truncation
mutants (Fig. 1B). We compared
the subcellular distribution of the
mutant proteins to the WT pro-
tein by heterologous expression of
truncation mutant forms of dys-
ferlin in WT Cav1 or Cav1/
MEFs (refer to summary table in Fig.
1). Full-length dysferlin efficiently
reaches the PM in WT Cav1 MEFs
(Fig. 1C), consistent with previous
results (18). In contrast, dysferlin
localized to intracellular structures
but not to the Golgi complex in
Cav1/ cells (Fig. 1C). GFP-2,
which lacks the three first C2
domains, was found tomainly local-
ize to the endoplasmic reticulum as
judged by a large overlap with the
endoplasmic reticulum marker,
protein-disulfide isomerase (Fig. 1,
C–E). Truncated versions of dysfer-
lin lacking the TM domain, GFP-3
and GFP-TM, were however,
mainly cytosolic (Fig. 1, C–E) and
were indistinguishable in WT Cav1
and Cav1/ cells.
In contrast to WT dysferlin and
to the above mutants, GFP-1,
which lacks the first four C2
domains,mostly accumulated in the
Golgi complex ofCav1/MEFs, as
demonstrated by colocalization
with the Golgi marker, GM130 (Fig.
1, C–E), but associated with the PM
in WT Cav1MEFs (Figs. 1C and 2).
To examine whether this reflected a
direct role of caveolin in facilitating
the transport of GFP-1 to the PM,
we co-expressed GFP-1 and HA-
tagged Cav1 (Cav1-HA) or Cav3
(Cav3-HA) in Cav1/ MEFs.
GFP-1 efficiently exited the Golgi
apparatus and reached the PM (Fig.
2). Quantitation showed that in
66% of Cav1/MEFs expressing
FIGURE 1. Subcellular distribution of dysferlin truncation mutants in Cav1/ cells. A, schematic
representations of full-length and truncation mutants of GFPDysf. B, baby hamster kidney cells were
transfectedwith either GFP or different GFPDysf constructs. Total cell lysates were separated in a 5.5% SDS
gel, electrotransferred, and immunoblotted using anti-GFP antibody. Truncated GFP-tagged mutants
appear as single polypeptides of predicted sizes. C, full-length dysferlin, GFPDysf, is mainly targeted to the
PM or to intracellular vesicles inWT Cav1 or Cav1/MEFs, respectively. GFP-C2 is mainly targeted to the
PM and to fine punctate structures. GFP-1 predominantly accumulates in the Golgi as demonstrated by
colocalization with the Golgi marker, GM130. GFP-2 is mostly concentrated in endoplasmic reticulum
shown by the extensive overlay with protein-disulfide isomerase, an endoplasmic reticulum marker,
whereas GFP-3 and GFP-TM are predominantly cytosolic.D, predominant subcellular phenotypes were
scored based on colabeling with relevant intracellular markers. Results are presented as percentage of
cells showing a prevalent phenotype, and are representative of three individual experiments (n 
30–350/for each construct). E, summary table of dysferlin constructs and subcellular localizations. Bar,
10 m.
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Cav1-HA or Cav3-HA, GFP-1 was localized to the PM and to
intracellular puncta (Fig. 2B). GFP-C2, amutant lacking all six
C2 domains was predominantly targeted to the PM in bothWT
Cav1 (not shown) and Cav1/ MEFs (Figs. 1, C–E, and 3, A
and B). Quantitation of Cav1/ MEFs expressing GFP-C2
showed that in97%of the cells, GFP-C2 localized to the PM.
Taken together these results show that GFP-1, which lacks
the first four C2 domains, predominantly accumulates in the
Golgi complex in the absence of caveolin. This suggests that
caveolin is required for GFP-1 transport from the Golgi com-
plex to the PM. In contrast, a mutant lacking all six C2 domains
is not retained in the Golgi complex
in the presence or absence of caveo-
lin. The loss of all six C2 domains
renders mutated dysferlin inde-
pendent of caveolin for surface
delivery.
The fact that GFP-C2 efficiently
reached the PM in Cav1/ MEFs
(Fig. 3) showed that this truncated
protein was not dependent on
caveolin for surface targeting. We
investigated whether a Golgi-local-
ized dystrophy mutant of Cav3
(Cav3P104L-HA), which causes
retention of full-length dysferlin in
the Golgi complex (18) would affect
the traffic of GFP-C2 to the PM.
Cells co-expressing epitope-tagged
Cav3P104L (Cav3P104L-HA) and
GFP-C2 showed a dramatic accu-
mulation in the Golgi complex (66%
of the cells) compared with cells
expressing mutated dysferlin alone
(4% of the cells) (Fig. 3). Thus
GFP-C2, which does not require
caveolin for Golgi exit and PM tar-
geting, is blocked in trafficking from
the Golgi by the P104L caveolin
mutant.
Characterization of Dysferlin Traf-
ficking in Cells Lacking Caveolin—
In the absence of caveolin dysferlin
accumulates in an intracellular
compartment of unknown nature.
The identification of these struc-
tures should provide insights into
the role of caveolins in dysfer-
lin trafficking. We first examined
whether dysferlin was targeted for
degradation in Cav1/ cells. How-
ever, dysferlin failed to co-localize
significantlywithmarkers of the late
endocytic pathway such as LBPA
and LAMP1 (supplemental Fig.
S1A). Despite the low surface label-
ing in the Cav1/MEFs, we spec-
ulated that dysferlin is able to reach
the PM but then is efficiently endocytosed in the absence of
caveolin. If this was the case, antibodies to the lumenal myc
epitope should be readily internalized by Cav1/ cells
expressing GFPDysf but not by WT Cav1 cells. WT Cav1 and
Cav1/ MEFs were transfected with a dysferlin cDNA con-
taining an N-terminal GFP tag and a C-terminal (lumenal/ex-
tracellular) myc tag (GFPDysf). After 4 h post-transfection,
antibodies against the dysferlin ectoplasmic myc tag were
added to the culture medium and antibodies were allowed to
internalize overnight. The cells were then fixed, permeabilized,
and labeledwith secondary antibodies. A striking accumulation
FIGURE 2. Cav1 and Cav3 redistribute GFP-1 from the Golgi to the plasmamembrane in Cav1/ cells.
MEF cells were transfected with GFPDysf or GFP-1 or co-transfected with GFP-1 and epitope-tagged Cav3-
HA, and colabeled with anti-HA or anti-Cav and anti-GM130 antibodies. A, in Cav1/ cells dysferlin is mainly
localized to punctate structures throughout the cytoplasm, whereas GFP-1mutant accumulates in the Golgi
complex as demonstrated by colocalization with the Golgi marker, GM130. Interestingly, expression of
epitope-tagged Cav3 redistributes GFP-1 to the PM. Similarly in WT Cav1 MEFs endogenous caveolin is
sufficient for GFP-1 Golgi exit and PM targeting. B, phenotype quantification. Cav1/ or WT Cav1 cells
expressing GFP-1 or co-expressing GFP-1 and Cav1-HA or Cav3-HA were subject to phenotype scoring.
Predominant subcellular phenotypes were scored based on colabeling with relevant intracellular markers.
Results are presented as percentage of cells showing a prevalent phenotype, and are representative of three
individual experiments (n 30–350/for each construct). Bar, 10 m.
Caveolin Regulation of Dysferlin
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ofmyc antibodies was observed in theCav1/MEFs (Fig. 4A),
very little was internalized in WT Cav1 and no uptake was
observed in neighboring non-transfected cells (see Fig. 4A)
indicating that the antibodies were taken up specifically after
binding to the exposed lumenal myc epitope and not by fluid
phase uptake. Consistent with this, the internalized antibodies
colocalized with GFPDysf. Identical results were obtained
when experimentswere performedusing Fab fragments against
the myc epitope (supplemental Fig. S1B). Cav1/ MEFs
expressing GFP-dysf showed higher uptake of Fab fragments
compared with WT Cav1 cells (supplemental Fig. S1B). There
was no colocalization of Fab fragments and transferrin in WT
Cav1 orCav1/ cells at any of the time points examined (data
not shown).
To investigate this in more detail, myc antibodies were
bound to the surface of GFPDysf expressing Cav1/ or WT
Cav1 cells at 4 °C and warmed for 30 min at 37 °C to allow
internalization of the antibodies. Surface antibodies were
removed by an acid wash. Interestingly, in WT Cav1 or
Cav1/ MEFs, significant GFPDysf internalization was
observed after 30 min. Despite the low level of PM dysferlin,
Cav1/MEFs containedmanymore vesicles positive for both
GFP andmyc (Fig. 4B) suggesting amuch higher endocytic rate.
This was confirmed by quantitation of the intracellular/PM
(IC/PM) ratio after uptake at 10min
(WT Cav1, IC/PM ratio  0.05 
0.001; Cav1/, IC/PM ratio 
0.52 0.04) and 40 min (WT Cav1,
IC/PM ratio  0.10  0.009;
Cav1/, IC/PM ratio  1.07 
0.12) (Fig. 4C). Furthermore, and
consistent with our previous work
(18), we predicted that re-expres-
sion of Cav1-HA in Cav1/MEFs
would inhibit dysferlin internaliza-
tion (Fig. 4D). Cav1/ MEFs
co-expressing GFPDysf and Cav1-
HA showed a distribution of dysfer-
lin similar to that seen in WT Cav1
MEFs (refer to supplemental Fig.
S2A); the ability of dysferlin to
reside at the PM membrane has
been rescued by expression of Cav-1
(Fig. 4D and supplemental Fig.
S2A). Thiswas further confirmed by
quantifying the amount of internal-
ized myc antibodies in WT Cav1
and Cav1/ MEFs expressing
GFPDysf (WT Cav1, 9.06  0.67;
Cav1/, 24.04 1.89) or Cav1/
cells co-expressing GFP-dysf and
Cav1-HA (9.33  0.56) (refer to
“Experimental Procedures”) (Fig.
4D). Thus these results demonstrate
that themajor effect of caveolin is to
retain dysferlin at the PM and
inhibit its internalization. These
results demonstrate that dysferlin is
not absolutely dependent on caveolin to reach the PM but is
efficiently retained at the PM in the presence of caveolin. Taken
together, these results show a hitherto unexpected dynamic
cycling of dysferlin in Cav1/ cells.
Dysferlin Is Internalized Through a Clathrin-independent
Endocytic Pathway—We next examined the pathway by which
dysferlin is internalized in Cav1/MEFs using transferrin to
label the clathrin pathway and cholera toxin binding subunit
(CTB) orGPI-anchored proteins (AP) asmarkers of other path-
ways. Myc antibodies taken up by expressed GFP-dysferlin for
various times did not colocalize significantly with transferrin
(Fig. 5A). However, significant colocalization of internalized
myc antibodies and CTB was evident after 2, 10, and 40 min of
internalization (Fig. 5A). No significant difference in the inter-
nalization rate of transferrin or CTB was seen between WT
Cav1 or Cav1/MEFs (supplemental Fig. S2B).
GPI-AP are internalized via a clathrin- and dynamin-inde-
pendent endocytic pathway (54–56). To test if dysferlin was
trafficking from the PM via this pathway we co-internalized
antibodies against the extracellular tags (mouse anti-myc for
dysferlin and rabbit anti-GFP for GPI-GFP). Cav1/ MEFs
co-expressing GFPDysf and GPI-GFP were labeled on ice with
anti-myc and anti-GFP antibodies, warmed to 37 °C for 2, 10,
and 40 min, and then acid-washed. Internalized antibodies
FIGURE 3. Dystrophy-associated mutant of Cav3 retains GFP-C2 in the Golgi complex. Cav1/ cells
were transfected with GFP-C2 or co-transfected with GFP-C2 or GFPDysf and HA-tagged Cav3P104L, and
colabeled with anti-HA and anti-GM130 antibodies. A, GFP-C2 is targeted to the PM and punctate structures
throughout thecytoplasm.As seenwith full-lengthdysferlin (18), expressionof epitope-taggedCav3P104L-HA
causes a dramatic redistribution ofGFP-C2 to theGolgi complex as judgedby triple labelingwith anti-GM130
antibody. B, phenotype quantification. Cav1/ cells expressing GFP-C2 or co-expressing GFP-C2 and
Cav3P104L-HA or GFPDysf and Cav3P104L-HA were subject to phenotype scoring. Predominant subcellular
phenotypes were scored based on colabeling with relevant intracellular markers. Results are presented as
percentage of cells showing a prevalent phenotype and are representative of three individual experiments
(n 30–350/for each construct). Bar, 10 m.
Caveolin Regulation of Dysferlin
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were detected with anti-mouse Alexa Fluor 546 and anti-rabbit
Alexa Fluor 647 antibodies after permeabilization. At all
time points endocytic vesicles containing myc and GFP anti-
bodies were readily detectable (Fig. 5A), demonstrating that
internalized dysferlin was targeted
to a GPI-AP enriched compart-
ment. We further investigated if
dysferlin vesicular traffic followed
a dynamin-dependent route using
the dynamin inhibitor, Dynasore
(57, 58). Whereas transferrin up-
take was blocked, dysferlin endo-
cytosis was unaffected by incuba-
tion with Dynasore (Fig. 5B). We
conclude that the major endocytic
pathway involved in dysferlin
endocytosis in Cav1/ cells is
dynamin-independent.
Ultrastructural Analysis of Dys-
ferlin Trafficking—To gain further
insights into dysferlin endocytosis,
Cav1/ or WT Cav1 MEFs were
transfected with GFP-dysf, then
incubated with anti-myc antibodies
followed by an anti-mouse HRP-la-
beled antibody at 4 °C. The cells
were then warmed for 2 min at
37 °C, and the DAB reaction visual-
ized in the presence or absence of
AA to identify internal structures, as
in previous studies (54). The cells
were then fixed and processed for
correlative light and electron
microscopy, identifying GFP-dysf-
expressing cells by light microscopy
and then sectioning the plastic
embedded cells for EM. Consistent
with the light microscopy, WT cells
showed a uniform, almost continu-
ous, layer of HRP reaction product
over the entire cell surface (WT
Cav1 AA; Fig. 6, A and B) and lit-
tle internal staining. No preferential
staining of caveolae was observed,
consistent with our previous immu-
noelectromicrograph studies (18).
In contrast, Cav1/MEFs showed
very patchy sparse labeling over the
cell surface (KOAA; Fig. 6, C and
D) but with some tubular profiles
apparently enriched in reaction
product (Fig. 6, E and G). Quantita-
tion of the surface coverage of the
HRP reaction product in WT Cav1
versus Cav1/ cells showed a far
higher surface coverage in the WT
Cav1 cells (see Fig. 6, A and C) con-
sistent with the low level of surface
labeling in Cav1/ cells as observed by light microscopy.
Endocytic structures were clearly observed in theCav1/ cells
treated with AA (KO  AA, Fig. 6, H and I). The ring-shaped
morphology and size of the labeled elements are consistentwith
FIGURE 4. Dysferlin cycles between an intracellular compartment and the plasma membrane.WT Cav1
and Cav1/MEFs were transfected with GFPDysf and allowed to internalized anti-myc antibodies overnight
or for 30 min at 37 °C. A, in bothWT and Cav1/ cells dysferlin is cycling between the PM and an intracellular
endocytic compartment. Inset showsextensive colocalizationbetweenGFPDysf and internalizedmyc antibod-
ies in Cav1/ cells (*, untransfected cell; **, cell expressing low levels of dysferlin) but inWT Cav1 cells there is
very little internalization. B, inWT Cav1MEFs dysferlin ismainly localized at the PMalthough some internalized
myc can be seen after 30 min (see inset). In contrast after 30 min of myc antibody internalization, dysferlin
shows a highly dynamic endocytic traffic in Cav1/ cells; inset, extensive overlay between GFPDysf and
internalized myc. C, time course of myc antibodies uptake in WT or Cav1/ MEFs expressing GFPDysf. The
mean fluorescence intensity of dysferlin associatedwith the PM (myc surface labeling) and internalizedmyc (2,
10, and 40 min chase at 37 °C) was measured and expressed as IC/PM ratio. D, dysferlin internalization is
rescued toWT levels by expression of epitope-taggedCav1 in Cav1/MEFs.WTCav1 andCav1/MEFswere
transfectedwith GFPDysf or co-transfectedwith GFPDysf and Cav1-HA and anti-myc antibodieswere internal-
ized for 20minat 37 °C. Themean fluorescence intensity of internalizeddysferlin (myc labeling)wasquantified.
Error bars are S.E. of three experiments (n 30). Bars, 10 m.
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structures labeled by CTB HRP in WT and Cav1/ MEFs in
the previous studies (54). These studies show that dysferlin is
retained over the entire cell surface in the presence of caveolin
but is rapidly internalized in its absence.
Dysferlin Trafficking Is Not Rescued by Caveolin Scaffolding
Domain Mutants in Cav1/ MEF Cells—To gain further
insights into the functional interaction between dysferlin and
caveolin and the relevance of these observations to muscle dis-
ease, we examined the effect of
caveolin mutants on dysferlin en-
docytosis as compared with wild
type caveolin. We made use of HA-
tagged CSD point mutants,
Cav3G55S (Cav3G55S-HA) and
Cav3C71W (Cav3C71W-HA) (50,
59), which have been linked to mus-
cular dystrophy (11, 13) and the
CSD deletion mutant, Cav181–
100 (Cav1-81–100-HA) (60).
Quantitation of surface versus intra-
cellular dysferlin was performed
using antibodies to the lumenalmyc
tag as in previous studies (18).
Cav3G55S-HA or Cav3C71W-HA
expressed in Cav1/ MEFs local-
ized predominantly at the surface in
a similar fashion to the wild type
protein (Fig. 7), whereas Cav181–
100-HA mainly targeted to the
Golgi complex as judged by colocal-
ization with the Golgi marker,
GM130 (Fig. 7). GFP-dysf was
largely localized to intracellular
puncta in Cav1/ cells (PM/IC
ratio 0.67  0.07) but PM associa-
tion was restored by re-expression
of either Cav1-HA (PM/IC ratio
1.99  0.96) or Cav3-HA (PM/IC
ratio 2.3  0.55) (18) (Fig. 8, A and
B). In contrast, expression of
Cav181–100-HA (PM/IC ratio
0.61  0.10), Cav3G55S-HA
(PM/IC ratio 0.65  0.15), or
Cav3C71W-HA (PM/IC ratio
1.16 0.57) did not affect dysferlin
traffic to the PM and dysferlin
remained enriched in intracellular
vesicles of Cav1/MEFs (Fig. 8B).
The lack of an inhibitory effect of
these mutants on dysferlin endo-
cytosis is also shown by the uptake
of myc antibodies when these
mutants are expressed together
with GFP-dysf, as compared with
the WT Cav3 protein (Fig. 8C).
The above results suggest that this
conserved domain of caveolin is
required for inhibition of dysferlin
endocytosis and its retention at the PM.
Dominant acting mutants of Cav3 cause a reduction in sur-
face Cav3, retention of Cav3 in the Golgi complex, and
increased degradation (61, 62). We have previously shown that
these mutants cause an accumulation of dysferlin in the Golgi
complex.We investigatedwhether this was a result of a block of
dysferlin exit from the Golgi rather than a consequence of
redistribution due to dysferlin instability at the PM in the
FIGURE 5. Dysferlin co-internalizes with the early endocytic markers CTB and GPI-AP in a dynamin-
independent manner. A, Cav1/ cells were transfected with GFP-dysf or co-transfected with GFP-dysf and
TFR or GPI-GFP. Anti-myc antibodies were co-internalizedwith fluorophore-conjugated Tfn or CTB or anti-GFP
antibodies for various times at 37 °C. Dysferlin is internalizedmainly via a non-clathrin pathway. No significant
colocalization is seen between internalized myc antibodies and Tfn. Dysferlin follows CTB and GPI in their
endocytic traffic. Extensive co-internalization is visualizedwith anti-myc (GFP-dysf) andCTB andGFP (GPI-GFP)
after 2, 10, and 40 min uptake. B, dynamin inhibitor, Dynasore, does not block dysferlin endocytic traffic.
Cav1/ MEFs were transfected with GFPDysf and incubated in 80 mM Dynasore, 0.4% Me2SO, Dulbecco’s
modified Eagle’s medium or 0.4% Me2SO, Dulbecco’s modified Eagle’s medium alone. Anti-myc antibody or
Tfn were internalized for 20 min at 37 °C. Inhibition of dynamin does not block the internalization of anti-myc
antibodies by dysferlin, whereas Tfn internalization was blocked. Bars, 10 m (A); 20 m (B).
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absence of caveolin. Nomyc antibody uptake was evident in the
perinuclear region or intracellular vesicles (Fig. 9A) suggesting
that dysferlin exit from the Golgi complex was blocked by the
dystrophy-associated mutant caveolin and that these mutants
have a dominant inhibitory role on Golgi exit. This effect of
caveolin-dystrophy mutants on dysferlin exit from the Golgi
complex is specific and not a result of their Golgi localization.
Expression of a CSD deletion mutant, Cav181–100, which is
also Golgi localized does not restrain dysferlin from exiting the
Golgi (Fig. 9B). Taken together, these results show two distinct
effects of caveolin mutants on trafficking of dysferlin.
DISCUSSION
In this work we have provided novel insights into dysferlin
trafficking dynamics with respect to caveolin. Through the use
of cells lacking caveolin, by expres-
sion of caveolin mutants, and by
using different mutants of dysferlin,
we have now identified the precise
steps in dysferlin trafficking that are
regulated by caveolin. We show
directly that caveolins can facilitate
exit of dysferlin mutants from the
Golgi complex. In addition, domi-
nant-acting caveolin mutants in-
hibit Golgi exit of mutant or wild
type dysferlin. However,most unex-
pectedly, we now show that the pri-
mary effect of caveolin is to inhibit
dysferlin endocytosis, implicating
an endocytic mechanism in caveo-
lin-associated muscle pathology.
Caveolin Modulation of Dysferlin
Exit from the Golgi Complex—In
cells devoid of caveolin dysferlin
accumulates in intracellular vesicu-
lar structures, which we now show
are endocytic in nature. No accu-
mulation was observed in the Golgi
complex and we demonstrated that
despite the lack of surface labeling,
dysferlin is rapidly transiting the cell
surface in these cells, as shown by
uptake of extracellular antibodies to
a lumenal tag. These results suggest
that dysferlin does not absolutely
depend on caveolin for Golgi exit.
Recent studies have suggested that
novel exocytic carriers, containing
defined quanta of caveolin, leave the
Golgi complex and fuse directly
with the PM (63). These carriers,
termed exocytic caveolar carriers
(64), form a novel exocytic pathway
distinct from classical exocytic car-
riers (see scheme in Fig. 10); these
carriers would presumably be
absent in cells lacking caveolin. Our
data provide new insights into these pathways. Full-length dys-
ferlin can clearly utilize a non-caveolar carrier pathway to reach
the PM, as shown inCav1/ cells. Similarly, a dysferlinmutant
lacking all six C2 domains (-C2) can also efficiently reach the
PM, both in the absence or presence of caveolin again showing
use of a non-caveolar carrier. However, in stark contrast to
these two constructs, a protein of intermediate length, which
lacks four C2 domains, shows an absolute dependence on
caveolin for exit from the Golgi complex (Fig. 2 and scheme in
Fig. 10). Whereas this is an artificially generated construct,
these results clearly demonstrate a role for caveolin in Golgi
exit, as suggested previously for a number of proteins including
the angiotensin receptor (59), insulin receptor (65), and the
stretch-activated channel, TRPC1 (66). The structural features
that make these proteins dependent on caveolin for Golgi exit
FIGURE 6. Ultrastructural characterization of dysferlin endocytosis in Cav1/ and WT Cav1 MEFs. WT
Cav1 or Cav1/ MEFs were transfected with GFPDysf and then after 14 h were incubated sequentially with
antibodies to the lumenal myc tag and then HRP-labeled secondary (anti-mouse) antibodies at 4 °C. The cells
were then warmed to 37 °C for 2 min to allow endocytosis to occur. The DAB reaction was performed on the
living cells at 4 °C in the presence (AA) or absence (AA) of ascorbic acid as indicated. After fixation the
transfected cells were identified under the light microscope by their GFP fluorescence and were marked to
allow subsequent identification after embedding in resin. The marked areas were sectioned and viewed
unstained. In the absence of AA, allowing visualization of both surface and intracellular pools of HRP, WT Cav1
cells showed HRP reaction product over the entire cell surface (A and B). In striking contrast, all transfected
Cav1/ cells showed sparse patchy surface labeling (C and D; arrowheads) consistent with greatly reduced
retention of dysferlin at the plasmamembrane. Quantitation of surface coverage by intersection counting (see
“Experimental Procedures”) showed that 10.3%of thePMofCav1/ cellswas covered inHRP reactionproduct
and 89.0% of the PM ofWT cells. Neighboring untransfected cells showed no trace of HRP labeling (results not
shown) demonstrating the specificity of the antibody labeling. Potential clathrin-independent early endocytic
carriers (arrowheads) were frequently observed in the Cav1/ cells (E–G). In the presence of ascorbic acid to
quench extracellular HRP, internal ring-shaped endocytic elements were clearly demonstrated in the Cav1/
cells (H and I). Bars, A–D, 1 m; E–I, 200 nm.
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are as yet, unclear. In the case of dysferlin, it appears that the
shorter construct is absolutely dependent on the caveolar path-
way, whereas the additional cytoplasmic region of the full-
length protein allows the protein to usemultiple pathways. This
might involve interaction of the terminal C2 domains with cel-
lular machinery involved in trafficking via these caveolin-inde-
pendent pathways. One candidate protein is Ahnak, which
interacts with the C2A domain of dysferlin (67). Ahnak is a
marker of a distinct exocytic vesicle, the enlargeosome (68, 69).
Consistent with a role for dysferlin in membrane repair (24),
enlargeosomes are proposed to be the source ofmembrane dur-
ing PM resealing (68). Although enlargeosomes do not associ-
atewith caveolin-enriched detergent-resistantmembranes (69)
it remains to be examined whether dysferlin exits the Golgi via
enlargeosomes. As C2 domains have also been implicated in
phospholipid binding it is also possible that interactionwith the
distinct domains of the Golgi membrane allow segregation of
dysferlin away from the caveolar domain.
Dystrophy Mutants of Caveolin Disrupt Golgi Exit of Both
Full-length Dysferlin and Dysferlin Truncation Mutants—We
have previously demonstrated that dystrophy-associated
mutants of caveolin (Cav3P104L and Cav3R26Q) cause dysfer-
lin accumulation within the Golgi complex (18). We find no
evidence for dysferlin transport to
the cell surface under these condi-
tions suggesting that the caveolin
mutants cause a complete block in
Golgi exit. Interestingly, this was
true for all the tested membrane-
associated dysferlin constructs,
including -C2, which lacks most
of the cytoplasmic domain and
traffics to the PM in a caveolin-
independent manner. This raises
the possibility that mutant caveo-
lin might perturb dysferlin traffick-
ing at an earlier stage in the Golgi
complex, before divergence of the
two pathways. Consistent with this,
Golgi caveolin mutants accumulate
throughout the Golgi complex
including the cis Golgi (18, 47). The
specificity of this effect is shown by
the fact that a Golgi-localized form
of caveolin lacking amino acids
81–100 does not prevent dysferlin
from exiting the Golgi. This sug-
gests that a direct interaction
between dysferlin and caveolin, at
least, at the Golgi level may be tak-
ing place. If so, this narrows down
the interacting domain of dysferlin
to the TM domain and nearby cyto-
plasmic region, which contains four
potential CSDbindingmotifs. How-
ever, these findings do not rule out
perturbation of lipid domains of the
Golgi complex, which may be influ-
enced by expression of a form of caveolin withmutations in this
potential lipid-binding domain (45). If so, these effects are
restricted to specific cargo proteins as the transit of other pro-
teins, such as GPI-anchored proteins, through the Golgi com-
plex is unaffected by the expression of themutant caveolin pro-
teins (18).
Caveolins Inhibit Dysferlin Endocytosis—We show here for
the first time that caveolins inhibit endocytosis of dysferlin. In
cells lacking Cav1 and Cav3, dysferlin is rapidly cleared from
the PM resulting in a low level of PM dysferlin in contrast to a
large intracellular pool at steady state. Our results show amuch
higher endocytic rate for dysferlin in Cav1/ cells as antibod-
ies to a lumenal tag accumulate far more rapidly in Cav1/
cells than in cells expressing Cav1 or Cav3 despite the higher
level of surface dysferlin in these cells (see Figs. 4 and 8) (18).
Expression of Cav1 or Cav3, but not specific caveolin mutants,
inhibits dysferlin endocytosis resulting in its retention at the
cell surface and a high level of PM dysferlin. Dysferlin endocy-
tosis in Cav1/ cells is via a dynamin (and caveolin-)-inde-
pendent pathway. Colocalization with GPI-anchored proteins
and CTB, but not transferrin, at early stages of endocytosis
strongly implicates the CLIC/GEEC clathrin-independent
pathway (54, 56) in dysferlin endocytosis. This is supported by
FIGURE7.Subcellulardistributionof caveolin scaffoldingdomainmutants.Cav1/ cellswere transfected
with HA-tagged Cav3, Cav3G55S, Cav3C71W, Cav181–100, and Cav3P104L, and colabeled with anti-HA and
anti-GM130 antibodies. A, similarly to the wild type Cav3, the CSDmutants Cav3G55S and Cav3C71W CSD are
targeted to the PM. In contrast, deletion of the CSD, Cav181–100, results in accumulation in the Golgi com-
plex similarly to the dystrophy mutant Cav3P104L, demonstrated by the extensive overlap with the Golgi
marker, GM130. B, CSD mutant predominant phenotypes were scored based on colabeling with relevant
intracellularmarkers. Results are presented as percentage of cells showing a prevalent subcellular localization,
and are representative of three individual experiments (n 30–250/for each construct). Bar, 10 m.
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ultrastructural analysis of the endo-
cytic pathway showing dysferlin in
tubular/ring-shaped early endoso-
mal elements. These results suggest
a novel role of this pathway in regu-
lating dysferlin surface expression
and, a role for caveolin in inhibiting
the clathrin-independent endocyto-
sis of specific markers.
The inhibitory effect of caveolins
on dysferlin endocytosis presents an
interesting conundrum. We believe
that a direct inhibitory effect of
caveolin by binding dysferlin to
immobile caveolar domains is
unlikely; both electron microscopy
and lightmicroscopy show that dys-
ferlin does not colocalize signifi-
cantly with caveolin, even at the
level of light microscopy, and both
immuno-EM on frozen sections
(18) and EM surface labeling exper-
iments (this study) confirmed that
dysferlin was not concentrated
within caveolae. Thus, the inhibi-
tion by caveolin appears to be indi-
rect. Yet our results suggest that the
effect of caveolin on dysferlin endo-
cytosis is specific; whereas acute
Cav1 expression has been shown to
inhibit clathrin-independent endo-
cytosis of CTB (54, 70) and SV40 is
efficiently internalized by cells
devoid of caveolae (71) CTB and
SV40 internalization was quantita-
tively identical in WT Cav1 and
Cav1/ MEFs as used here. Fur-
thermore, no effect on GPI-AP
internalization could be detected in
Cav1/ cells. This argues against a
general negative inhibitory role of
caveolins on clathrin-independent
endocytosis, but suggests that
caveolins specifically inhibit dysfer-
lin entry into this pathway. We
could also show that the increased
uptake of dysferlin in Cav1/ cells
was not due to increased endocyto-
sis caused by dysferlin expression
(results not shown). Caveolae have
been suggested to be negative regu-
lators of clathrin-independent
endocytosis (70, 72) but other work
identifies caveolae as endocytic
vehicles (73–75). A new concept
described here is that caveolin is
regulating the non-caveolar endo-
cytosis of dysferlin as we have
FIGURE 8. Dysferlin retention at the PM is dependent on an intact CSD. Expression of CSD point
mutants does not rescue dysferlin traffic to the PM in Cav1/ MEF cells. Cav1/ cells were transfected
with GFPDysf or co-transfected with GFPDysf and HA-tagged Cav3, Cav3G55S, Cav3C71W, Cav181–100,
and Cav3P104L and labeled with rabbit anti-HA and mouse anti-myc antibodies. Surface labeling of
dysferlin and quantification of PM and intracellular pools of dysferlin were performed as described under
“Experimental Procedures.” A, in cells lacking caveolin dysferlin is mainly targeted to intracellular puncta
throughout the cytoplasm.Whereas expression of epitope-tagged Cav3 rescues dysferlin traffic to the PM,
expression of CSD mutants (i.e. Cav3G55S) does not rescue dysferlin traffic to the PM. B, the mean fluo-
rescence intensity of dysferlin associated with the PM (myc labeling) and intracellular structures (GFP
labeling) was measured and expressed as the PM/IC ratio. Error bars are S.E. of three experiments (n 30);
**, p	 0.001. C, Cav1/ cells co-expressing GFPDysf and HA-tagged, Cav3C71W, Cav3G55S, or Cav3 were
allowed to uptake anti-myc antibodies for 10 min at 37 °C. Expression of Cav3C71W or Cav3G55S, but not
WT Cav3 protein, have no effect on dysferlin endocytosis as demonstrated by the internalization of
anti-myc antibodies. Bars, 10 m.
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clearly demonstrated that dysferlin is not concentrated in
caveolae.
A model for the inhibitory effect of caveolin on endocytosis
must take into account the intriguing finding that two Cav3
single point mutants, which occur naturally in the human pop-
ulation, did not inhibit dysferlin endocytosis in complete con-
trast to the wild type protein. This implicates the scaffolding
domain of caveolin in its inhibitory activity. The two inhibitory
mutants were initially reported as dystrophy mutants (11) but
subsequently have been shown to occur as polymorphisms in
the population (76, 77). Yet two previous studies have shown
specific effects of these mutant proteins in cultured cells (50,
59). Further studies should elucidate the underlying mecha-
nisms involved in the inhibitory activity of the wild type protein
in comparison to these single point mutants and whether these
mutations can contribute to disease under certain conditions.
In conclusion, these studies have elucidated distinct roles of
caveolin in regulating dysferlin trafficking pathways, both in
positively regulating exocytosis and negatively regulating endo-
cytosis via a clathrin-independent pathway for which dysferlin
acts as a new marker. An interesting possibility is that this
inhibitory activity of caveolin on endocytosis is regulated in
vivo, allowing modulation of the surface levels of dysferlin and
membrane remodeling.Whether caveolin acts in a similar fash-
ion on other surface proteins will require further investigation.
The involvement of endocytosis in muscle disease may be a
more general phenomenon. Another sarcolemmal protein,
-sarcoglycan, which is linked to a subset of muscle disease
limb girdle muscular dystrophy 2D (78, 79), is translocated
from the cell surface to endosomes upon perturbation of its PM
stability (80). -Sarcoglycan stability at the PM relies on a
proper assembly of the sarcoglycan complex (80). Thus dysfer-
lin and -sarcoglycan represent examples of sarcolemmal pro-
teins where endocytic mechanisms play a central role in main-
taining the integrity of the PM.
These results provide new insights into the functions of
caveolins and the mechanisms underlying caveolin-related dis-
eases. In addition, they provide fundamental insights into the
regulation of exocytic and endocytic trafficking pathways of
membrane proteins in mammalian cells and the importance of
this poorly characterized clathrin-independent endocytic path-
way in surface remodeling of specific PM components.
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SUPPLEMENTARY MATERIAL 
 
Figure S1. (A) Dysferlin is not localized to late endosomes in Cav1-/- MEFs. Cav1-/- MEFs 
expressing GFP-dysf were immunolabeled with markers of the late endosomal/lysosomal 
compartments. Dysferlin is targeted to an endosomal compartment that is distinct from late-
endosomal/lysosomal structures. There is no evident colocalization with LBPA- or LAMP-1 positive 
compartments. 
(B) Expression of Cav1 rescues dysferlin endocytic phenotype in Cav1-/- MEFs. WT Cav1 and 
Cav1-/- MEFs were transfected with GFP-dysf or co-transfected with GFP-dysf and Cav1-HA and 
anti-myc antibodies were internalized for 20 min at 37ºC. Cells were labeled with antibodies against 
endogenous caveolin or the HA tag. Dysferlin internalization is rescued to WT levels by expression of 
HA-tagged Cav1 in Cav1-/- MEFs. Very few punctate structures colabeled with GFP-dysf. 
Internalised anti-myc antibodies are seen in WT or Cav1-/- MEFs expressing GFP-dysf or 
coexpressing GFP-dysf and Cav1-HA, respectively. In contrast, Cav1-/- MEFs expressing GFP-dysf 
alone show extensive overlap with internalised anti-myc.  
(C) WT and Cav1-/- MEFs have similar endocytic rates. WT Cav1 and Cav1-/- MEFs were 
allowed to internalise Tfn or CTB for 10min at 37ºC. There is no significant difference in the rate of 
endocytosis between WT and Cav1-/- MEFs as shown by quantification of the mean fluorescence 
intensity of internalized Tfn or CTB. Error bars are ± SD (n= 30). Bars, (A-B) 10µm. 
 
Figure S2. Anti-myc IgGs and Fab fragments do not affect the endocytosis mechanism of 
dysferlin in MEFs. WT Cav1 (not shown) and Cav1-/- MEFs were transfected with GFP-dysf. IgGs 
or Fab fragments of anti-myc antibodies were cointernalized with Tfn for 40min at 37oC. There was 
no difference in the extent of internalization between anti-myc IgGs and Fab fragments in WT (not 
shown) and Cav1 -/- MEFs. Consistent with results shown in Figure 4, Cav1-/- MEFs internalize 
more IgGs or Fabs compared to WT Cav1 MEFs (not shown). Bars, 10µm. 
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